Drug Response Prediction

We have characterized 1000 human cancer cell lines and screened them with 100s of compounds. On this website, you will find drug response data and genomic markers of sensitivity. The Genomics of Drug Sensitivity in Cancer Project - http://www.cancerrxgene.org/ - was part of a Wellcome Trust-funded collaboration between The Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This collaboration integrated the expertise at both sites toward the goal of identifying cancer biomarkers that can be used to identify genetically defined subsets of patients most likely to respond to cancer therapies. We screened >1000 genetically characterized human cancer cell lines with a wide range of anti-cancer therapeutics. These compounds included cytotoxic chemotherapeutics as well as targeted therapeutics from commercial sources, academic collaborators, and the biotech and pharmaceutical industries. The sensitivity patterns of the cell lines were correlated with extensive genomic and expression data to identify genetic features that are predictive of sensitivity. This large collection of cell lines enabled us to capture much of the genomic heterogeneity that underlies human cancer, and which appears to play a critical role in determining the variable response of patients to treatment with specific agents.

Abstract: First released in 2006, DrugBank (https://go.drugbank.com) has grown to become the 'gold standard' knowledge resource for drug, drug-target and related pharmaceutical information. DrugBank is widely used across many diverse biomedical research and clinical applications, and averages more than 30 million views/year. Since its last update in 2018, we have been actively enhancing the quantity and quality of the drug data in this knowledgebase. In this latest release (DrugBank 6.0), the number of FDA approved drugs has grown from 2646 to 4563 (a 72% increase), the number of investigational drugs has grown from 3394 to 6231 (a 38% increase), the number of drug-drug interactions increased from 365 984 to 1 413 413 (a 300% increase), and the number of drug-food interactions expanded from 1195 to 2475 (a 200% increase). In addition to this notable expansion in database size, we have added thousands of new, colorful, richly annotated pathways depicting drug mechanisms and drug metabolism. Likewise, existing datasets have been significantly improved and expanded, by adding more information on drug indications, drug-drug interactions, drug-food interactions and many other relevant data types for 11 891 drugs. We have also added experimental and predicted MS/MS spectra, 1D/2D-NMR spectra, CCS (collision cross section), RT (retention time) and RI (retention index) data for 9464 of DrugBank's 11 710 small molecule drugs. These and other improvements should make DrugBank 6.0 even more useful to a much wider research audience ranging from medicinal chemists to metabolomics specialists to pharmacologists. #### More Information: - Paper: DrugBank 6.0: the DrugBank Knowledgebase for 2024 - PMID: 37953279 - PMCID: PMC10767804 - DOI: 10.1093/nar/gkad976 Knox, C., Wilson, M., Klinger, C. M., Franklin, M., Oler, E., Wilson, A., Pon, A., Cox, J., Chin, N. E. L., Strawbridge, S. A., Garcia-Patino, M., Kruger, R., Sivakumaran, A., Sanford, S., Doshi, R., Khetarpal, N., Fatokun, O., Doucet, D., Zubkowski, A., Rayat, D. Y., … Wishart, D. S. (2024). DrugBank 6.0: the DrugBank Knowledgebase for 2024. Nucleic acids research, 52(D1), D1265–D1275. https://doi.org/10.1093/nar/gkad976